AUTOIMMUNE INFLAMMATORY TWIN

Organ-on-chips are the present of research,
a new class of laboratory models resulting
from the best micro-bioengineering techniques
that outperform current preclinical in vitro
and in vivo models.

AUTOIMMUNE INFLAMMATORY TWIN

Organ-on-chips are the present of research, a new class of laboratory models resulting from the best micro-bioengineering techniques that outperform current preclinical in vitro and in vivo models.

A DIGITAL TWIN
FOR PERSONALIZED MEDICINE

AI-TWIN aims at developing a new generation of in vitro systems, based on personalized and fully autologous organ on chip

AI-TWIN products are state of the art, unique and innovative in their genre, thanks to their immunological approach and to the attention in the use of autologous biological components. The company conducts research, development and production of products and methodologies oriented towards personalized medicine.

A DIGITAL TWIN FOR PERSONALIZED MEDICINE

AI-TWIN aims at developing a new generation of in vitro systems, based on personalized and fully autologous organ on chip

AI-TWIN products are state of the art, unique and innovative in their genre, thanks to their immunological approach and to the attention in the use of autologous biological components. The company conducts research, development and production of products and methodologies oriented towards personalized medicine.

FUTURE PERSPECTIVES

Our research represents a turning point for clinical practice, the pharmaceutical industry, and academia.

We aim at developing a new generation of in vitro systems, the next-generation personalized organ on chip (OoC).

They are created with the use of a microfluidic device, starting from patient biopsies, useful for advanced research on new treatments and permitting patient-specific clinical trials-on-chip.

 

Models more faithful to the patient’s anatomo-physiology

Lowering costs for drug screenings

Translational research to identify new therapeutic markers

Improved patient care
and reduced side effects

FUTURE PERSPECTIVES

Our research represents a turning point for clinical practice, the pharmaceutical industry, and academia.

We aim at developing a new generation of in vitro systems, the next-generation personalized organ on chip (OoC).

They are created with the use of a microfluidic device, starting from patient biopsies, useful for advanced research on new treatments and permitting patient-specific clinical trials-on-chip.

 

Models more faithful to the patient’s anatomo-physiology

Lowering costs for drug screenings

Translational research to identify new therapeutic markers

Improved patient care
and reduced side effects

FOUNDERS

Annalisa Chiocchetti
CEO

Lia Rimondini
Founder

FOUNDERS

Annalisa Chiocchetti
CEO

Lia Rimondini
Founder

PARTNERS

PARTNERS

Ai-Twin srl

info@aitwin.it

Sede legale e operativa
C.so Trieste, 15/A – 28100 Novara (NO)

C.F./P.IVA 02722210032
SDI SUBM70N